/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. AI For Pharma Growth
  2. E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer
E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth · Jul 28, 2026

"Doing AI" isn't a strategy. Pharma leaders must shift from activity-based pilots to a value-driven, financially modeled portfolio.

AI Failure Stems from a Dependency Chain of Four Structural Flaws, Not Isolated Issues

Successful AI implementation requires solving four issues in sequence: 1) Value Prioritization, 2) Decision Rights, 3) Data Governance, and 4) Incentive Architecture. Solving these out of order leads to wasted effort, such as redesigning incentives for tools that can't scale.

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer thumbnail

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth·7 days ago

A Governable AI Strategy Must Be Falsifiable, Not Just Aspirational

Vague answers like 'We're doing AI' are impossible for a board to govern because they can't be proven wrong. A genuine strategy presents a clear thesis with specific metrics, timelines, and financial projections, giving the board something concrete to hold leadership accountable to.

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer thumbnail

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth·7 days ago

Crowdsourcing AI Strategy from Business Units Leads to Competitor Copying, Not Innovation

Asking business units for AI ideas results in them suggesting what they've seen from competitors or vendors. This approach imports another company's strategic context, which is likely a poor fit for your own, leading to mediocrity.

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer thumbnail

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth·7 days ago

An AI Strategy Requires Compounding Initiatives, Not Just a Collection of Defensible Pilots

While every AI pilot may be individually justifiable, they often fail to be collectively coherent. A true strategy exists when initiatives build on one another, creating compounding value—like when clinical data feeds medical affairs AI. A collection of disconnected projects cannot be governed effectively.

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer thumbnail

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth·7 days ago

AI Business Cases Fail When They Equate 'Time Saved' With Financial Benefit

Finance departments rightfully reject business cases that claim value from 'time saved' by AI. To be credible, the model must explicitly state how that saved time will be redeployed: to remove costs, increase throughput, or enable higher-value work. Without this, it's not a real financial model.

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer thumbnail

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth·7 days ago

Low AI Tool Adoption Is a Rational Economic Decision by Employees, Not a Behavioral Flaw

Employees don't adopt AI tools when the personal cost is immediate and visible, while the benefit is delayed, uncertain, and accrues to the organization, not their individual performance review. The solution is redesigning incentives, not more training.

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer thumbnail

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth·7 days ago